肿瘤防治研究2025，Vol.52Issue(6)：491-495,5.DOI:10.3971/j.issn.1000-8578.2025.25.0101
BRCA1/2突变HER2阳性乳腺癌的临床特征及其对新辅助靶向治疗的反应
Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy
摘要
Abstract
Objective To analyze the proportion and clinicopathological characteristics of HER2-positive breast cancer patients with BRCA1/2 pathogenic variants,and their response to neoadjuvant anti-HER2 targeted therapy.Methods The clinicopathological data of 531 breast cancer patients with germline BRCA1/2 pathogenic variants(201 with BRCA1 variants and 330 with BRCA2 variants)were analyzed.Results Among the 201 BRCA1 and 330 BRCA2 variants,17(8.5%)and 42(12.7%)HER2-positive breast cancer cases were identified,respectively,accounting for 11.1%of all BRCA1/2-mutated breast cancers.Compared with BRCA1/2-mutated HR-positive/HER2-negative patients,HER2-positive patients did not present any significant differences in clinicopathological features;however,compared with triple-negative breast cancer patients,HER2-positive patients had a later onset age and lower tumor grade.Among the 17 patients who received neoadjuvant anti-HER2 targeted therapy,10 cases achieved pCR(58.8%),whereas 7 cases did not(41.2%).Conclusion HER2-positive breast cancer accounts for more than 10%of BRCA1/2-mutated patients.Approximately 40%of these patients fail to achieve pCR after neoadjuvant targeted therapy.This phenomenon highlights the possibility of combining anti-HER2 targeted agents with poly(adenosine diphosphate-ribose)polymerase inhibitors.关键词
BRCA1/2突变/HER2阳性乳腺癌/临床特征/新辅助治疗Key words
BRCA1/2 pathogenic variant/HER2-positive breast cancer/Clinicopathological characteristic/Neoadjuvant therapy分类
临床医学引用本文复制引用
廖兴宇,刘慧敏,孙洁,胡丽,张娟,姚璐,徐晔,解云涛..BRCA1/2突变HER2阳性乳腺癌的临床特征及其对新辅助靶向治疗的反应[J].肿瘤防治研究,2025,52(6):491-495,5.基金项目
Key Supported Project of the Major Research Program of the National Natural Science Foundation of China(No.92359201) （No.92359201）
National Natural Science Foundation of China General Program(No.82272932,82473481) 国家自然科学基金重大研究计划重点支持项目(92359201) （No.82272932,82473481）
国家自然科学基金面上项目(82272932、82473481) （82272932、82473481）
